{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:52:27Z","timestamp":1792266747620,"version":"4.4.0"},"reference-count":17,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:p>Because nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) express CD20, rituximab may be used as a nonmutagenic treatment option to avoid late toxicities in this rather indolent entity. Between 1999 and 2004, the German Hodgkin Study Group (GHSG) investigated the activity of rituximab (375 mg\/m2 in 4 doses) in a phase 2 trial in 21 relapsed or refractory NLPHL patients. The initial diagnosis of NLPHL was confirmed in 15 of the 21 enrolled patients by reference pathology. The remaining cases were reclassified as Hodgkin lymphoma transformed to T-cell rich B-cell lymphoma (TCRBCL; n = 2) or CD20+ classical Hodgkin lymphoma (cHL; n = 4). In NLPHL patients the overall response rate was 94%, including 8 complete remission (CR) and 6 partial remission (PR). With a median follow-up of 63 months (range, 3-84), the median time to progression was 33 months, with the median overall survival (OS) not reached. Thus, rituximab is highly effective in relapsed and refractory NLPHL. This study is registered at http:\/\/www.klinisches-studienzentrum.de\/trial\/285.<\/jats:p>","DOI":"10.1182\/blood-2007-03-078725","type":"journal-article","created":{"date-parts":[[2007,10,15]],"date-time":"2007-10-15T20:44:26Z","timestamp":1192481066000},"page":"109-111","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":149,"title":["Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)"],"prefix":"10.1182","volume":"111","author":[{"given":"Holger","family":"Schulz","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Rehwald","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"Hospitalier de Universitaire Lille, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Elter","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Driessen","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"R\u00fcdiger","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Wuerzburg, Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schnell","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Diehl","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111822572819800_B1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019111822572819800_B2","volume-title":"WHO Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe","year":"2001"},{"key":"2019111822572819800_B3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/13.S1.44","article-title":"Worhshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell\/histiocyte-rich B cell lymphoma.","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"key":"2019111822572819800_B4","first-page":"15","article-title":"[The prognosis of Hodgkin's disease according to the histologic type and the clinical stage. Role of the reactions of the host].","volume":"6","author":"Lukes","year":"1966","journal-title":"Nouv Rev Fr Hematol"},{"key":"2019111822572819800_B5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/1097-0142(19830615)51:12<2293::AID-CNCR2820511221>3.0.CO;2-X","article-title":"Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas.","volume":"51","author":"Miettinen","year":"1983","journal-title":"Cancer"},{"key":"2019111822572819800_B6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","article-title":"Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.","volume":"101","author":"Rehwald","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111822572819800_B7","first-page":"77","article-title":"Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group.","volume":"2","author":"Cosset","year":"1991","journal-title":"Ann Oncol"},{"key":"2019111822572819800_B8","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.2003.01.079","article-title":"Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection\u2013a Study of the French Society of Pediatric Oncology.","volume":"21","author":"Pellegrino","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111822572819800_B9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"key":"2019111822572819800_B10","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"key":"2019111822572819800_B11","first-page":"1889","article-title":"European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.","volume":"96","author":"Anagnostopoulos","year":"2000","journal-title":"Blood"},{"key":"2019111822572819800_B12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0609.2005.00462.x","article-title":"Lymphocyte-predominant and classical Hodgkin's lymphoma\u2013comparison of outcomes.","volume":"75","author":"Nogova","year":"2005","journal-title":"Eur J Haematol Suppl"},{"key":"2019111822572819800_B13","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood.V108.11.2742.2742","article-title":"Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: improvement of event free survival (EFS) in all international prognostic score (IPS) groups [abstract].","volume":"108","author":"Younes","year":"2006","journal-title":"Blood"},{"key":"2019111822572819800_B14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0046-8177(89)80007-3","article-title":"Nodular paragranuloma can transform into high-grade malignant lymphoma of B type.","volume":"20","author":"Hansmann","year":"1989","journal-title":"Hum Pathol"},{"key":"2019111822572819800_B15","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2003-02-0626","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell\/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell\/histiocyte-rich B-cell lymphoma.","volume":"102","author":"Boudov\u00e1","year":"2003","journal-title":"Blood"},{"key":"2019111822572819800_B16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00000478-199201000-00006","article-title":"Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.","volume":"16","author":"Delabie","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"2019111822572819800_B17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00000478-199602000-00008","article-title":"T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease.","volume":"20","author":"McBride","year":"1996","journal-title":"Am J Surg Pathol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/1\/109\/1219548\/zh800108000109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/1\/109\/1219548\/zh800108000109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:57:35Z","timestamp":1574117855000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/1\/109\/107898\/Rituximab-in-relapsed-lymphocytepredominant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-03-078725","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}